KRAS and cancer: By calculating site-specific neutral cancer cell mutation rates in sequenced SCLC tumors, we can quantify the relative strength of selection driving prevalence of KRAS G12C in comparison to known SCLC drivers, gaining insight into the potential therapeutic efficacy of a KRAS G12C inhibitor.2